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Hasslacher and colleagues have provided a new piece of 
data regarding pleiotropic eﬀ  ects of levosimendan [1]. In 
their elegantly designed study, the authors showed in 
both in vitro and in vivo experiments that levosimendan 
‘cools down’ oxidative burst in polymorphonuclear neutro-
phils, and hence prevents or decreases the deleterious 
eﬀ  ects of reactive oxygen species.
Levosimendan is known not only to be an inodilator 
but also to exert cellular protective eﬀ  ects by antioxidant, 
anti-inﬂ   ammatory, anti-apoptotic properties [2-4]. 
Herein, the authors seem to puzzle out one piece of the 
whole pathophysiologic mechanism driving septic-shock-
induced myocardial dysfunction. Interesting enough, in 
patients with septic shock, oxidative burst activity was 
cooled down in unstimulated as well as in stimulated 
poly  morphonuclear neutrophils, whereas in patients 
with acute heart failure only stimulated oxidative burst 
was cooled down by levosimendan. We think that the 
clinical meaning of such a diﬀ  erential eﬀ  ect deserves to 
be investigated in future studies. It is possible to turn 
such net improvements into clinically meaningful beneﬁ  t 
providing that the time, route and mode of administration 
are well controlled.
Decreased respiratory burst activity of polymorpho-
nuclear neutrophils in the study could possibly be driven 
by the membrane hyperpolarizing eﬀ  ect of levosimendan 
or phosphodiesterase III inhibitory eﬀ   ects, which is 
mainly observed at high doses. Actually, measuring 
plasma levels of levosimendan could have been helpful in 
understanding which mechanism dominated. Whatever 
the mechanism, such an eﬀ  ect should be kept in mind to 
tailor the therapy of patients suﬀ  ering from potentially 
hazardous complications of excess reactive oxygen 
species including septic shock. Of note, upon preload 
optimization by ﬂ  uid administration and/or vasopressor 
treatment in the study, levosimendan treatment seemed 
to be well accepted by the patients. However, the reason 
for the lack of a relationship between a decrease in 
oxidative burst and survival might be linked to the time 
of initiation of drug administration. Inotropic therapy is 
usually considered a last option in many patients, and 
oxidative burst could possibly have already done its 
irreversible injury in such patients. We think the present 
study provides a unique opportunity to move faster in 
decision-making and therapy.
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Abstract
Levosimendan, in addition to its inotropic properties, 
could have anti-infl  ammatory and anti-oxidative 
properties, and can potentially decrease the 
deleterious eff  ects of reactive oxygen species on 
the tissues. In their study, Hasslacher and colleagues 
provided not only in vitro but also in vivo evidence that 
levosimendan could preserve organ function in acute 
heart failure and septic-shock-induced myocardial 
depression via cooling down the oxidative burst of 
circulating cells.
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